Tools for Practice Outils pour la pratique

#101 NSAIDs and cardiovascular safety: the truth makes my heart hurt

Do different non-steroidal anti-inflammatory drugs (NSAIDs) have different cardiovascular risks?

COX-2 inhibitors and traditional NSAIDs, except naproxen, increase the risk of major vascular events and death. When prescribing NSAIDs, patients’ gastrointestinal (GI) and cardiovascular (CV) risk should be assessed, with naproxen or low-dose ibuprofen preferentially chosen for patients at risk of CV disease.  

CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session

Meta-analysis of 754 randomized controlled trials (~350,000 patients):1 
  • Mixed population, primarily arthritis, at low-moderate CV risk (i.e. CV event rate ~1% per year). 
  • COX-2 inhibitors, compared to placebo, increased: 
    • All-cause mortality, Rate Ratio (RR) 1.22 (95% Confidence Interval 1.041.44). 
    • Major CV events, RR 1.37 (1.141.66). 
  • Diclofenac (150 mg/day)similar risks to COX-2s for mortality [RR 1.02 (0.84–1.24)] and CV events [RR 0.97 (0.84–1.12)]. 
    • Indirectly, diclofenac significantly increases CV events [RR 1.41 (1.12–1.78)] but not mortality [RR 1.20 (0.94–1.54)] compared to placebo. 
  • Naproxen (1000 mg/day) has less CV events and mortality than COX-2 inhibitors and may be similar to placebo. 
  • Relative risk similar between patients with or without prior CV disease. 
Meta-analysis of observational trials:2 
  • All COX-2s and NSAIDs, except naproxen and low-dose ibuprofen (≤1200 mg/day), increase CV risk.   
  • Risk increases with increasing NSAID dose.  
Results are consistent with previous meta-analysis.3  Context:   
  • In Canada, naproxen (28%), celecoxib (21%), and diclofenac (17%) account for the majority of NSAIDs prescribed.4 
  • The magnitude of the CV risk with high-risk NSAIDs is similar to the magnitude of the CV benefit with statin therapy. Choosing high-risk NSAIDs (taken daily) can cause one additional CV event over five years in:1 
    • ~10low-risk patients (baseline 5% ten-year CV risk). 
    • ~25 high-risk patients (baseline 20% ten-year CV risk). 
  • Generally, NSAIDs with relatively lower CV risks (naproxen) have relatively higher GI complication risks (ulcers and bleeds) and vice versa (coxibs).5 
    • Adding a proton pump inhibitor to a non-selective NSAID results in similar GI complication risks as COX-2s.6 
  • All NSAIDs increase risk of heart failure.1  

Latest Tools for Practice
Derniers outils pour la pratique

#363 Making a difference in indifference? Medications for apathy in dementia

In patients with dementia, how safe and effective are stimulants, antidepressants, and antipsychotics for treating apathy?
Read Lire 0.25 credits available Crédits disponibles

#362 Facing the Evidence in Acne, Part I: Oral contraceptives and spironolactone in females

How effective are combined oral contraceptives (COC) and spironolactone for treating acne of at least mild-moderate severity in females?
Read Lire 0.25 credits available Crédits disponibles

#361 Preventing RSV Infections in Infants

How safe and effective are monoclonal antibodies to prevent respiratory syncytial virus (RSV) infections in infants?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session

  • G. Michael Allan MD CCFP
  • Megan Harbin BScPharm ACPR
  • Michael R Kolber BSc MD CCFP MSc
  • Ricky D. Turgeon BSc(Pharm) ACPR PharmD

1. Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Lancet. 2013; 382(9894):769–79.

2. McGettigan P, Henry D. PLoS Med. 2011; 8(9):1–18.

3. Trelle S, Reichenbach S, Wandel S, et al. BMJ. 2011; 342:c7086.

4. McGettigan P, Henry D. PLoS Med. 2013; 10(2):1–6.

5. Castellsague J, Riera-Guardia N, Calingaert, et al. Drug Saf. 2012; 35(12):1127–46.

6. Wang X, Tian HJ, Yang HK, et al. Eur J Gastroenterol Hepatol. 2011; 23:876–80.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.